Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension
Conclusions:
This study showed that OLM/AML/HCTZ reduced blood pressure and significantly increased blood pressure control whilst improving patients’ HRQoL. Achieving blood pressure control, amount of concomitant medication and dosage strength of antihypertensive impacted on patients’ HRQoL. (Source: BioMed Central)
Source: BioMed Central - February 21, 2015 Category: Journals (General) Authors: Pedro Marques da SilvaUwe HaagJulian F GuestJohn E BrazierMarco Soro Source Type: research
Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers
Conclusions Probenecid increases the exposure speed of olmesartan by increasing the AUC0–48, AUC0→∞, and Css-av. The combined treatment of olmesartan medoxomil with probenecid may increase the occurrence of genitourinary side effects. ClinicalTrials.gov identifier: NCT01907373. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - November 2, 2014 Category: Drugs & Pharmacology Source Type: research
Health-Related Quality Of Life Impact Of Triple Combinations Of Olmesartan Medoxomil, Amlodipine Besylate And Hydrochlorothiazide In Subjects With Hypertension
A secondary objective of a phase-III study spanning 54 weeks was to measure changes in the health-related quality of life (HRQoL) of 2,690 patients ≥18 years of age with moderate-to-severe hypertension who ended up receiving one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) using the MINICHAL and EQ5D instruments. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: U. Haag, J.F. Guest, M. Soro Source Type: research
Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy.
This study aimed to evaluate the efficacy and safety of olmesartan medoxomil (OM)/amlodipine (AML) 20/5 mg fixed-dose combination tablet in Chinese mild to moderately hypertensive patients with inadequate blood pressure (BP) control on monotherapy. Two multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group clinical trials were conducted. After screening and a 2-week placebo run-in period, patients with 95 mmHg ≤ seated diastolic blood pressure (SeDBP) < 110 mmHg received monotherapy with OM 20 mg (in Study 1) or AML 5 mg (in Study 2), once daily for 4 weeks. Patients with 90 mmHg...
Source: Archives of Pharmacal Research - July 25, 2014 Category: Drugs & Pharmacology Authors: Zhu JR, Zhang SY, Gao PJ Tags: Arch Pharm Res Source Type: research
Central composite design for validation of hptlc method for simultaneous estimation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in tablets
Trupti B. Solanki, Purvi A. Shah, Kalpana G. PatelIndian Journal of Pharmaceutical Sciences 2014 76(3):179-187High performance thin layer chromatographic method for simultaneous estimation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide was developed and validated as per ICH guidelines. Moreover, robustness testing was performed applying a central composite design with k factor having 2 k factorial runs, 2k axial experiments and two center points. High performance thin layer chromatographic separation was performed on aluminium plates precoated with silica gel 60F 254 and toluene:chloroform:methanol:ac...
Source: Indian Journal of Pharmaceutical Sciences - June 21, 2014 Category: Drugs & Pharmacology Authors: Trupti B. SolankiPurvi A. ShahKalpana G. Patel Source Type: research
Electrochemical studies of olmesartan medoxomil and its detection in pharmaceutical dosage forms and biological fluids by cathodic adsorptive stripping voltammetric method
The electrochemical properties of olmesartan (OLME) were investigated by cyclic voltammetry (CV) and differential pulse voltammetry (DPV) at hanging mercury drop electrode (HMDE). All studies were based on the irreversible and adsorption-controlled electrochemical reduction signal of OLME at about -1.2 and -1.5 V vs. Ag/AgCl at pH 5.0 in Britton-Robinson (BR) buffer. This adsorptive character of the molecule was used to develop a novel, fully validated, rapid, selective and simple differential pulse cathodic adsorptive stripping voltammeric (DPCAdSV) method for the direct determination of OLME in pharmaceutical dosage form...
Source: Journal of the Brazilian Chemical Society - June 3, 2014 Category: Chemistry Source Type: research
An Efficient Synthetic Method and Theoretical Calculations of Olmesartan Methyl Ether. Study of Biological Function of AT1 Antagonism.
Abstract
The dissolution of the antihypertensive AT1 antagonist olmesartan in methanol generates in situ a new highly bioactive methyl ether analogue via SN1 mechanism involving an intramolecular proton transfer from carboxyl to hydroxyl group. Theoretical calculations confirmed the thermodynamic control preference of methyl ether versus the antagonistic product methyl ester. Α facile synthetic method for olmesartan methyl ether from olmesartan or olmesartan medoxomil is also described. Interestingly, the introduction of the methyl group to olmesartan did not alter its pharmacological properties. This obs...
Source: Combinatorial Chemistry and High Throughput Screening - May 29, 2014 Category: Chemistry Authors: Ntountaniotis D, Agelis G, Resvani A, Halabalaki M, Liapakis G, Spyridaki K, Grdadolnik SG, Merzel F, Kostidis S, Potamitis C, Tselios T, Matsoukas J, Skaltsounis LA, Mavromoustakos T Tags: Comb Chem High Throughput Screen Source Type: research
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow-Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation [Hypertension]
Conclusions
Development of microalbuminuria is a valid marker for future CV events. RAS blockade with Olmesartan might cause sustained reduction (legacy effect) of micro- and macrovascular events. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - April 25, 2014 Category: Cardiology Authors: Menne, J., Ritz, E., Ruilope, L. M., Chatzikyrkou, C., Viberti, G., Haller, H. Tags: Hypertension Source Type: research
High throughput microwell spectrophotometric assay for olmesartan medoxomil in tablets based on its charge-transfer reaction with DDQ.
Abstract
Abstract The study describes the development and validation of a new microwell-based spectrophotometric assay for determination of olmesartan medoxomil (OLM) in tablets. The formation of a colored charge-transfer (CT) complex between OLM as an n-electron donor and 2,3-dichloro- -5,6-dicyano-1,4-benzoquinone (DDQ) as a p-electron acceptor was investigated, and employed as the basis for the development of the new assay. The proposed assay was conducted in 96-microwell plates. The absorbance of the colored-CT complex was measured at 460 nm with a microplate reader. Optimum conditions of the reaction ...
Source: Acta Pharmaceutica - March 1, 2014 Category: Drugs & Pharmacology Authors: Darwish IA, Wani TA, Khalil NY, Abdel-Rahman HM Tags: Acta Pharm Source Type: research
Measurement
and Correlation of Solubility of Olmesartan
Medoxomil in Six Green Solvents at 295.15–330.15 K
Industrial & Engineering Chemistry ResearchDOI: 10.1021/ie404373n (Source: Industrial and Engineering Chemical Research)
Source: Industrial and Engineering Chemical Research - February 5, 2014 Category: Chemistry Authors: Faiyaz Shakeel, Nazrul Haq, Fars K. Alanazi and Ibrahim A. Alsarra Source Type: research
Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study
Conclusion:
Treatment with OM/AM/HCTZ achieved superior (SBP) ABPM reductions compared with mono, dual or triple drug therapy, resulting in all patients achieving systolic ABPM goal without ABPM documented hypotension. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - February 3, 2014 Category: Cardiology Authors: Punzi, H. A. Tags: Original Research Source Type: research
Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients
This study reports in essential hypertensive patients the effect of 6 months treatment with olmesartan on plasma level of CGRP and number and survival of cEPCs.
Methods and results: In 20 essential hypertensive patients treated with olmesartan medoxomil (20 mg per day for 6 months), cEPCs (CD34+KDR+, CD133+KDR+ and CD34+CD133+KDR+) (direct 3-color flow cytometry analysis), apoptosis of cEPCs (CD133+KDR+ cells with Annexin V expression), CGRP determination (ELISA) and HO-1 protein level (western blot) were assessed at baseline and after 3 and 6 months of treatments. Olmesartan normalized blood pressure (P (Source: Journal of Hypertension)
Source: Journal of Hypertension - December 17, 2013 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research
Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Abstract
Olmesartan medoxomil (OM) is hydrolyzed to its active metabolite olmesartan by the action of aryl esterase to exert its antihypertensive actions by selectively blocking angiotensin II-AT1 receptor. Poor aqueous solubility and uncontrolled enzymatic conversion of OM to its poorly permeable olmesartan limits its oral bioavailability. The aim of the current study was to formulate a novel nanoemulsion of OM to improve its pharmacokinetics and therapeutic efficacy. The oil-in-water (o/w) nanoemulsion of OM was developed using lipoid purified soybean oil 700, sefsol 218 and solutol HS 15. We have charac...
Source: Colloids and Surfaces - December 16, 2013 Category: Biotechnology Authors: Gorain B, Choudhury H, Kundu A, Sarkar L, Karmakar S, Jaisankar P, Pal TK Tags: Colloids Surf B Biointerfaces Source Type: research
[Severe Enteropathy with Villous Atrophy Olmesartan Medoxomil-associated.]
PMID: 24246126 [PubMed - as supplied by publisher] (Source: Therapie)
Source: Therapie - November 11, 2013 Category: Psychiatry & Psychology Authors: Nunge D, Eoche M, Fumery M, Nguyen-Khac E, Gras V, Andréjak M Tags: Therapie Source Type: research
Olmesartan Linked to Spruelike Enteropathy
* There appears to be a relationship between the antihypertensive drug olmesartan medoxomil and spruelike enteropathy. This condition develops after long-term use of the drug, usually two years or more after the start of therapy.
* Patients who develop diarrhea and weight loss but don't have celiac sprue should be taken off olmesartan. (Source: AJN)
Source: AJN - November 1, 2013 Category: Nursing Tags: Drug Watch Source Type: research
